This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
"Never catch a falling knife" is the Wall Street adage traders cling to during volatile markets like these. If you ask us, they may want to avoid a falling
Javelin(JAV) as well.
Shares of Javelin Pharmaceuticals lost a quarter of their value Monday after the company said its licensee for the pain treatment Dyloject has withdrawn all batches of the drug from the U.K.
Therabel Pharma UK Ltd. yanked Dyloject after finding the presence of a "white particulate matter" in some of its vials.
What's the matter with a little extra "matter," you ask?
Well, aside from safety questions and the
ick factor, this unexplained "matter" matter could undermine a major merger. (Say that sentence three times fast and you may need a pain treatment yourself!)
Javelin, you see, is the subject of an all-cash, $145 million tender offer, or $2.20 per share, from drug and medical device maker
Hospira(HSP), which snatched the company from rival
Myriad Pharmaceuticals(MYRX) in April with a better offer. After Monday's selloff, Javelin's market cap has been reduced to $80 million, and its shares now trade around $1.20 a share.
Javelin stranded Myriad at the altar last month. Now it is the one being sacrificed.
Dumb-o-meter score: 75 -- Javelin is unravelin'.